Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery System; Company is Currently Conducting…
Application Update Based on Extensive Review of DataGLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:…
Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial…
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of…
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year…
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued…
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE)…
Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidatesIambic to receive up to $25…
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as…